The intravenous use of commercial disinfectants in the treatment of Novel Coronavirus (COVID-19): Unconventional, but is there evidence against it?

Authors

  • Adarsh Shah Senior Clinical Research Fellow, Centre of Healthcare Education and Research, University of Aberdeen, Aberdeen, AB25 2ZD
  • Edmund Leung Consultant Surgeon, Base Hospital, Westown, New Plymouth, New Zealand 4310 https://orcid.org/0000-0003-3710-1035

DOI:

https://doi.org/10.3126/ajms.v11i4.28941

Keywords:

Disinfectant, COVID, Hypochlorite, Intravenous drug users

Abstract

Background: On 24th April 2020, United States President Donald J. Trump suggested the use of commercial surface disinfectants to treat patients infected with COVID-19. In his speech, President Trump also proposed medical research be conducted. However, there are controversies regarding the toxicity of the disinfectant’s main ingredients sodium hypochlorite.

Aims and Objective: The purpose of this international collaborative study is to assess on feasibility and safety of disinfectants in human use.

Materials and Methods: Several safety labels of common commercialised brands of surface disinfectant from United Kingdom and New Zealand. Furthermore, literature search was conducted through Pubmed on keywords keywords “sodium hypochlorite” AND “poisoning” AND “intravenous drug user”.

Result: All safety labels advised hazardous warning regarding irritation and caustic burns if ingested. They all suggest water to wash out the effect if exposed to any mucus membrane such as eyes and broken skin. No safety information was given by any of the brands against subcutaneous or intravenous injection. No death in human was reported resulting from oral ingestion. There were 2 case reports: one of blindness and one of fibrosing alveolitis resulting from ingestion during a domestic dispute. Intravenous injection has only been seen in attempted murder cases or by intravenous drug users. All the reported cases have resulted in 2 deaths, organ failures and venous thrombosis including pulmonary embolism.

Conclusion: There is no safety warning from the manufacturers of the studied surface disinfectants regarding intravenous use. Intravenous injections in the literature suggests significant toxic outcome including death. Randomised controlled trials on animals may be required to assess the risk of intravenous injection of surface disinfectants against the risk of death from COVID-19 infection.

Downloads

Download data is not yet available.
Abstract
786
PDF
386
Cover 11(4)

Downloads

Published

2020-07-01

How to Cite

Shah, A., & Leung, E. (2020). The intravenous use of commercial disinfectants in the treatment of Novel Coronavirus (COVID-19): Unconventional, but is there evidence against it?. Asian Journal of Medical Sciences, 11(4), 84–86. https://doi.org/10.3126/ajms.v11i4.28941

Issue

Vol. 11 No. 4 (2020)

Section

Short Communications

License

Authors who publish with this journal agree to the following terms:

  1. The journal holds copyright and publishes the work under a Creative Commons CC-BY-NC license that permits use, distribution and reprduction in any medium, provided the original work is properly cited and is not used for commercial purposes. The journal should be recognised as the original publisher of this work.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).